TrioxBio

Nitric Oxide Synthase Inhibitors

Health Tech & Life Sciences
Non Active, Jan 2022 ceased to operate

Company Overview

Snapshot

Founded in July 2015 by Shlomo Sadoun and Roy Farfara, TrioxBio operates with 1–10 employees. The company received Fast Track Designation from the U.S. FDA in May 2018 for Raviten® for the treatment of intradialytic hypotension.

Business overview

TrioxBio develops and commercializes proprietary synthetic small molecules designed to treat pathological conditions caused by the overproduction of nitric oxide. The company's core technology involves nitric oxide synthase (NOS) inhibitors, such as MTR-104, which block nitric oxide production to prevent detrimental effects like blood vessel dilation. TrioxBio serves the healthcare and life sciences industries, focusing on pharmaceuticals, and is involved in R&D for oncology, antiviral diseases, and new drug-delivery systems as part of SK Pharma Group.

Strategic signal

In May 2018, TrioxBio's lead candidate, Raviten® (MTR-107), received Fast Track Designation from the U.S. FDA for the treatment of intradialytic hypotension. This designation indicates the FDA's recognition of the drug's potential to address an unmet medical need, signaling a faster development and review process, which is a significant validation for investors in the pharmaceutical and biotech sectors.

Company Intelligence Q&A

What is TrioxBio's primary focus?
TrioxBio focuses on developing and commercializing proprietary synthetic small molecules that act as nitric oxide synthase (NOS) inhibitors to treat conditions caused by excessive nitric oxide production.
When was TrioxBio founded?
TrioxBio was founded in July 2015 by Shlomo Sadoun and Roy Farfara.
What significant regulatory milestone did TrioxBio achieve for Raviten®?
In May 2018, TrioxBio announced that Raviten® (MTR-107) received Fast Track Designation from the U.S. FDA for the treatment of intradialytic hypotension.
Which product received Orphan Drug Designation?
TrioxBio's leading candidate, MTR-107, received Orphan Drug Designation from the FDA in August 2016 for the prevention of recurrent intradialytic hypotension.
What is the status of TrioxBio?
TrioxBio is Non Active, having ceased to operate in January 2022.

External links